Skip to content
Markets News
Earnings1 min read

arGEN-X Revenue Jumps, but Operating Profit Misses Forecasts

Makkler Newsroom
October 22, 2026 · Based on reporting by finanzen.net

Third-quarter sales rose more than half, while operating profit came in below analysts’ average estimate as costs increased.

Key takeaways

  • Third-quarter revenue rose more than half year over year to $1.72 billion.
  • Operating profit increased 40% to $486 million, below the $551 million analyst average.
  • Research and marketing costs weighed on results.

arGEN-X reported third-quarter revenue of $1.72 billion, up more than half from a year earlier, as sales of its Vyvgart drug drove growth. Operating profit rose 40% to $486 million, but missed the $551 million average expected by analysts surveyed by Bloomberg.

The company said higher research and marketing costs weighed on results. Nearly all revenue came from Vyvgart, according to the report.

Net income attributable to shareholders was $506 million, compared with $344 million a year earlier.

Topics
ARGX
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.